Gravity Analytica

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SLDB 01.08.2025

SERA-AI Powered Highlights

Date of Upcoming Event:2025-01-15

Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference

Full Press Release SEC Filings Our SLDB Tweets

About Gravity Analytica

Recent Filings

01.13.2025 - 4 Statement of changes in beneficial ownership of securities

CHARLESTOWN, Mass.,Jan. 08, 2025(GLOBE NEWSWIRE) --Solid Biosciences Inc.(Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced thatBo Cumbo, President and CEO, will present at the 43^rdAnnualJ.P. Morgan Healthcare ConferenceonWednesday, January 15, 2025, at3:45 p.m. PT(6:45 p.m. ET).

A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or byclicking here. A webcast replay will be archived for 30 days on the Events page.

Institutional investors interested in meeting with management during the conference may reach out to their J.P. Morgan representatives.

AboutSolid BiosciencesSolid Biosciencesis a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-212 for the treatment of Friedreich’s ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visitwww.solidbio.com.

Solid Biosciences Investor Contact:Nicole AndersonDirector, Investor Relations and Corporate CommunicationsSolid Biosciences Inc.investors@solidbio.com

Media Contact:Glenn SilverFINN Partnersglenn.silver@finnpartners.com

Source: Solid Biosciences Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com